Swipe om te navigeren naar een ander artikel
The online version of this article (doi:10.1007/s12471-014-0522-3) contains supplementary material, which is available to authorized users.
Aspirin is associated with gastrointestinal side effects such as gastric ulcers, gastric bleeding and dyspepsia. High-dose effervescent calcium carbasalate (ECC), a buffered formulation of aspirin, is associated with reduced gastric toxicity compared with plain aspirin in healthy volunteers, but at lower cardiovascular doses no beneficial effects were observed.
To compare the prevalence of self-reported gastrointestinal symptoms between low-dose plain aspirin and ECC.
A total of 51,869 questionnaires were sent to a representative sample of the Dutch adult general population in December 2008. Questions about demographics, gastrointestinal symptoms in general and specific symptoms, comorbidity, and medication use including bioequivalent doses of ECC (100 mg) and plain aspirin (80 mg) were stated. We investigated the prevalence of self-reported gastrointestinal symptoms on ECC compared with plain aspirin using univariate and multivariate logistic regression analyses.
A total of 16,715 questionnaires (32 %) were returned and eligible for analysis. Of these, 911 (5 %) respondents reported the use of plain aspirin, 633 (4 %) ECC and 15,171 reported using neither form of aspirin (91 %). The prevalence of self-reported gastrointestinal symptoms in general was higher in respondents using ECC (27.5 %) compared with plain aspirin (26.3 %), but did not differ significantly with either univariate (OR 1.06, 95 %CI 0.84–1.33), or multivariate analysis (aOR 1.08, 95 %CI 0.83–1.41). Also, none of the specific types of symptoms differed between the two aspirin formulations.
In this large cohort representative of the general Dutch population, low-dose ECC is not associated with a reduction in self-reported gastrointestinal symptoms compared with plain aspirin.
Supplementary Table 1 (DOCX 29 kb)12471_2014_522_MOESM1_ESM.docx
Antithrombotic Trialists’ (ATT) Collaboration, Baigent C, Blackwell L, et al. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomized trials. Lancet. 2009;373(6978):1849–60. PubMed
Petroski D. Endoscopic comparison of three aspirin preparations and placebo. Clin Ther. 1993;15(2):314–20. PubMed
The Netherlands Foundation for Pharmaceutical Statistics/ www.s2.nl; Facts and Figures of 2012; accessed on May 21st 2013.
Van Marrewijk CJ, Mujakovic S, Fransen GA, et al. Effect and cost-effectiveness of step-up versus step-down treatment with antacids, H2-receptor antagonists, and proton pump inhibitors in patients with new onset dyspepsia (DIAMOND study): a primary-care-based randomised controlled trial. Lancet. 2009;373(9659):215–25. PubMedCrossRef
Likert R. A technique for the measurement of attitudes. Arch Psychol. 1932;140:55.
College voor zorgverzekeringen/ www.medicijnkosten.nl; accessed on July 25th 2013.
- Gastrointestinal symptoms in low-dose aspirin users: a comparison between plain and buffered aspirin
J. Jaspers Focks
M. M. Tielemans
L. G. M. van Rossum
M. A. Brouwer
J. B. M. J. Jansen
R. J. F. Laheij
F. W. A. Verheugt
M. G. H. van Oijen
- Bohn Stafleu van Loghum